Nuclear Science and Techniques

《核技术》(英文版) ISSN 1001-8042 CN 31-1559/TL     2019 Impact factor 1.556

Nuclear Science and Techniques ›› 2013, Vol. 24 ›› Issue (6): 060302 doi: 10.13538/j.1001-8042/nst.2013.06.017

• NUCLEAR CHEMISTRY,RADIOCHEMISTRY,RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE • Previous Articles     Next Articles

131I-chTNT-mediated radioimmunotherapy for non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma

GAO Shi1 JI Tiefeng 1 WEN Qiang 1 CHEN Bin 1 MA Qingjie 1#br# CHEN Zuowei 2 LIU Lin 1,*   

  1. 1China-Japan Union Hospital, Jilin University, Changchun 130033, China
    2Department of Nuclear Medicine, People’s Hospital of Shenzhen, Shenzhen 518020, China
  • Contact: LIU Lin E-mail:liulin5413@126.com
  • Supported by:

    Supported by the National Natural Science Foundation of China (NSFC) projects (No.81271606) and the Research Fund of Science and Technology Department of Jilin Province (Nos. 201015185 and 201201041) and the Research Fund of Shenzhen Sci-tech Department of Guangdong Province (No.201102154).

PDF ShareIt Export Citation
GAO Shi, JI Tiefeng, WEN Qiang, CHEN Bin, MA Qingjie. 131I-chTNT-mediated radioimmunotherapy for non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma.Nuclear Science and Techniques, 2013, 24(6): 060302     doi: 10.13538/j.1001-8042/nst.2013.06.017

Abstract:

In this paper, the safety and efficacy of 131I-labeled mouse/human chimeric monoclonal antibody (131I-chTNT)-mediated radioimmunotherapy are evaluated because the patients have non-uptaking 131I pulmonary metastases from differentiated thyroid carcinoma (DTC). The 16 patients were injected intravenously by 29.6±3.7 MBq·kg–1 using 131I-chTNT. The chest computer tomography was performed before treatment, as well as 28 and 70 days after treatment. Responses and safety were assessed during the treatment. The results show that the 131I-chTNT infusion was well tolerated with the 12.5% complete response, 18.8% partial response, 25.0% progressive disease, and the 43.8% stable disease, indicating that most treatment-related adverse effects are mild transient and reversible. The 131I-chTNT is promising for patients with non-uptaking the 131I pulmonary metastases from DTC.

Key words: 131I-chTNT, Pulmonary metastases, Differentiated thyroid carcinoma, Micronucleus